GxP Metadata and Lineage Evidence Director — Vaccine Manufacturing

The mandate

Batch investigations rely on laboratory, historian, MES and manually curated process-science data whose identifiers and effective versions do not align. Teams can usually reconstruct a narrative through expert effort, but cannot show a consistent evidence chain from sample and instrument through transformation to release judgement. An inspection-readiness review found that the enterprise catalogue records systems, not the critical context needed to reproduce decisions.

The deliverable is a GxP Metadata and Lineage Evidence Standard applied to four high-risk journeys: assay result, environmental monitoring, process deviation and continued verification. It will include identity rules, contextual metadata, transformation trace, audit-trail links, effective dating, exception handling and evidence retrieval. A validated reference implementation and migration decision must distinguish authoritative records from useful analytical copies.

Milestone one in week four provides journey evidence maps and critical-context gaps. Week nine concludes milestone two with the metadata model, control specification and validation plan. At week fifteen, milestone three delivers two end-to-end reference implementations and simulated inspection retrieval. The final standard, validation package, backlog and operating ownership are due at week twenty-two.

Acceptance requires Quality reviewers not involved in design to reconstruct three unseen release or investigation decisions within four hours from retained evidence, including every manual correction and transformation version. Computer System Validation must approve intended use and test results; Internal Audit must trace sampled metadata to sources. The quality chief accepts only after process scientists reproduce the chain without consultant assistance.

The client will provide controlled access to LIMS, MES, historian, instrument, quality and analytical environments; sample and batch identity standards; audit trails; validation records; and investigation histories. System owners will execute privileged extraction and configuration. Quality will arbitrate record status, while an internal validation lead will maintain requirements and approve testing inside the pharmaceutical quality system.

Why this is external work

System teams optimise local records, and process scientists bridge gaps through tacit knowledge that has never been engineered into traceability. Quality needs a neutral design not tied to a new catalogue sale or a single application’s worldview. External specialists can combine metadata architecture with validated decision evidence while internal staff prepare for inspection and continue manufacturing support.

What you will own

• Map sample, material, equipment, method, batch, parameter and decision identities across laboratory, manufacturing, historian and quality records.
• Define contextual metadata and effective-time rules needed to interpret values after method, specification, instrument or process changes.
• Trace transformations, manual interventions, exclusions and corrections from authoritative source through analytical use and final quality judgement.
• Design exception controls for missing identifiers, inaccessible contract-lab evidence, retrospective mappings and records whose status remains disputed.
• Build and validate two reference journeys with requirements, tests, trace matrices, evidence retention and controlled operating procedures.
• Exercise inspection retrieval through unseen scenarios measuring completeness, interpretive consistency, elapsed time and dependence on individual memory.
• Transfer stewardship, change control, periodic review and migration decisions to named Quality, science and data owners.

Candidate qualifications

• Led metadata or lineage programmes in GMP manufacturing, regulated laboratories or validated life-sciences environments with inspection exposure.
• Reconstructed batch, assay or process decisions across LIMS, MES, historian, instrument and analytical layers while preserving authoritative-record distinctions.
• Defined effective-time and contextual metadata where method, specification, calibration or process changes altered interpretation of historic values.
• Worked within computer-system validation and data-integrity controls without treating a catalogue screenshot as proof of GxP traceability.
• Conducted inspection simulations that revealed dependence on tacit scientist knowledge and converted the gap into a sustainable control.
• Delivered architecture and operating ownership independent of software resale, leaving internal Quality able to retrieve evidence without external support.

Non-negotiables

• The named director must lead evidence mapping in Vienna and attend validation and inspection simulations at relevant manufacturing sites.
• No reseller, implementation quota or referral payment may exist with catalogue, lineage, LIMS, MES or data-platform vendors considered.
• Authoritative record status and GxP release decisions remain with client Quality and cannot be reassigned through architecture.
• All manufacturing and patient-relevant evidence must stay in validated, access-controlled environments with approved extraction procedures.

1. 49 words maximum. Describe a GxP decision whose apparent lineage failed because method, instrument or effective-time context was missing.
2. 49 words maximum. How would you distinguish an authoritative record from a useful analytical copy across LIMS and manufacturing systems?
3. 49 words maximum. Which unseen inspection scenario would test whether internal staff can retrieve the evidence without tacit expert help?